Skip to main content
SpringerLink
Log in

Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells

  • Brief Report
  • Published:
Advances in Therapy Aims and scope Submit manuscript

Abstract

Introduction

This clinical study aimed to investigate the effect of brinzolamide, a topical carbonic anhydrase inhibitor, on corneal endothelial cells (CECs) in patients with glaucoma using a follow-up clinical study design.

Methods

Patients with primary open-angle glaucoma or ocular hypertension were administrated an ophthalmic solution of either latanoprost alone (LT) as a control (n = 18) or latanoprost plus brinzolamide (LT + BR; n = 16). CECs were examined at baseline and at 4, 12, 24, and 48 weeks in 18 and 16 eyes of the LT and LT + BR groups, respectively, using a non-contact specular microscope. CECs were evaluated by parameters, including cell density (CD), coefficient of variation (CV) in cell size, and percentage hexagonality (Hex).

Results

Compared with the baseline intraocular pressure (IOP), the mean IOP in the LT group was significantly reduced at 12 and 24 weeks, whereas that in the LT + BR group was significantly reduced at all time points (P < 0.01). The mean CD, CV, and Hex at baseline were not significantly different between the two groups. No significant time-course changes in CD, CV, or Hex were observed in either group. At 48 weeks, there was no significant difference in the mean CD, CV, or Hex between the two groups.

Conclusion

Patients treated with LT + BR showed significant IOP reduction. However, the use of brinzolamide in addition to latanoprost had no influence on CECs during the one-year follow-up period.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Anderson DR. Collaborative normal tension glaucoma study. Curr Opin Oppthalmol. 2003;16:297–303.

    Google Scholar 

  2. Van der Valk R, Webers CA, Schouten JS, et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: a meta-analysis of randomized clinical trials. Ophthalmology. 2005;112:1177–85.

    Article  PubMed  Google Scholar 

  3. Garway-Heath DF, Crabb DP, Bunce C. Latanoprost for open-angle glaucoma (UKGTS): a randomized, multicenter, placebo-controlled trial. Lancet. 2015;385:1295–304.

    Article  CAS  PubMed  Google Scholar 

  4. Schmier JK, Hulme-Lowe CK, Covert DW. Adjunctive therapy patterns in glaucoma patients using prostaglandin analogs. Clin Ophthalmol. 2014;8:1097–104.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Tanna AP, Rademaker AW, Stewart WC, Feldman RM. Meta-analysis of the efficacy and safety of alpha2-adrenergic agonists, beta-adrenergic antagonists, and topical carbonic anhydrase inhibitors with prostaglandin analogs. Arch Ophthalmol. 2010;128:825–33.

    Article  CAS  PubMed  Google Scholar 

  6. Holló G. Carbonic anhydrase inhibitors. In: Shaarawy T, Sherwood M, Hitchings R, Crowston J, editors. Glaucoma volume 1: medical diagnosis and therapy. Philadelphia: Elsevier & Saunders; 2009. p. 539–46.

    Google Scholar 

  7. Konowal A, Morrison JC, Brown SV, Cooke DL, Maguire LJ, Verdier DV, et al. Irreversible corneal decompensation in patients treated with topical dorzolamide. Am J Ophthalmol. 1999;127:403–6.

    Article  CAS  PubMed  Google Scholar 

  8. Kaminski S, Hommer A, Koyuncu D, Biowski R, Barisani T, Baumgartner I. Influence of dorzolamide on corneal thickness, endothelial cell count and corneal sensibility. Acta Ophthalmol Scand. 1998;76:78–9.

    Article  CAS  PubMed  Google Scholar 

  9. Lass JH, Khosrof SA, Laurence JK, Horwitz B, Ghosh K, Adamsons I, the Dorzolamide Corneal Effects Study Group. A double-masked, randomized 1-year study comparing the corneal effects of dorzolamide, timolol, and betaxolol. Arch Ophthalmol. 1998;116:1003–10.

    Article  CAS  PubMed  Google Scholar 

  10. Miura K, Ito K, Okawa C, Sugimoto K, Matsunaga K, Uji Y. Comparison of ocular hypotensive effect and safety of brinzolamide and timolol added to latanoprost. J Glaucoma. 2008;17:233–7.

    Article  PubMed  Google Scholar 

  11. Nakamoto K, Yasuda N. Effect of concomitant use of latanoprost and brinzolamide on 24-hour variation of IOP in normal-tension glaucoma. J Glaucoma. 2007;16:352–7.

    Article  PubMed  Google Scholar 

  12. Prum BE Jr, Rosenberg LF, Gedde SJ, Mansberger SL, Stein JD, Moroi SE, Herndon LW Jr, Lim MC, Williams RD. Primary Open-Angle Glaucoma Preferred Practice Pattern® Guidelines. Ophthalmology. 2016;123:41–111.

    Article  Google Scholar 

  13. Walland MJ. Glaucoma treatment in Australia: changing patterns of therapy 1994–2003. Clin Exp Ophthalmol. 2004;32:590–6.

    Article  Google Scholar 

  14. Lin JC. The use of ocular hypotensive drugs for glaucoma treatment: changing trend in Taiwan from 1997 to 2007. J Glaucoma. 2015;24:364–71.

    Article  PubMed  Google Scholar 

  15. Cheng JW, Cai JP, Wei RL. Meta-analysis of medical intervention for normal tension glaucoma. Ophthalmology. 2009;116:1243–9.

    Article  PubMed  Google Scholar 

  16. Wu KY, Wang HZ, Hong SJ. Cellular cytotoxicity of antiglaucoma drugs in cultured corneal endothelial cells. Kaohsiung J Med Sci. 2007;23:105–11.

    Article  CAS  PubMed  Google Scholar 

  17. Wu KY, Hong SJ, Wang HZ. Effects of antiglaucoma drugs on calcium mobility in cultured corneal endothelial cells. Kaohsiung J Med Sci. 2006;22:60–7.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors. All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship for this manuscript, take responsibility for the integrity of the work as a whole, and have given the final approval for the version to be published.

Disclosures

Tadashi Nakano received consultant fees from Topcon Corporation and lecture fees from Alcon Japan Ltd, Santen Pharmaceutical Co., Ltd, Otsuka Pharmaceutical Co., Ltd, R-Tech Ueno Ltd, Senju Pharmaceutical Co., Ltd, Carl Zeiss Co., Ltd, Kaken Pharmaceutical Co., Ltd, MSD K.K., and Pfizer Japan Inc. Rishu Inoue has received lecture fees from Santen Pharmaceutical Co., Ltd. Tairo Kimura has received lecture fees from Santen Pharmaceutical Co., Ltd, Alcon Japan Ltd, Otsuka Pharmaceutical Co., Ltd, Senju Pharmaceutical Co., Ltd, KOWA Pharmaceutical Co., Ltd, and Carl Zeiss Co., Ltd, ROHTO Pharmaceutical Co., Ltd, and CREWT Medical Systems, Inc. Hirotaka Suzumuza has received lecture fees from Santen Pharmaceutical Co., Ltd, Alcon Japan Ltd, Senju Pharmaceutical Co., Ltd, KOWA Pharmaceutical Co., Ltd, and Kowa Company Ltd. Tomihiko Tanino has received fees for expert testimony from KOWA Pharmaceutical Co., Ltd, lecture fees from Alcon Japan Ltd, Senju Pharmaceutical Co., Ltd, KOWA Pharmaceutical Co., Ltd, Ellex, Inc. and Pfizer Japan Inc. Yoshio Yamazaki has received lecture fees from Alcon Japan Ltd, Santen Pharmaceutical Co., Ltd, Pfizer Japan Inc., Otsuka Pharmaceutical Co., Ltd, Senju Pharmaceutical Co., Ltd, and KOWA Pharmaceutical Co., Ltd. Keiji Yoshikawa has received fees for expert testimony from Santen Pharmaceutical Co., Ltd, and lecture fees from Alcon Japan Ltd, Santen Pharmaceutical Co., Ltd, Pfizer Japan Inc., Otsuka Pharmaceutical Co., Ltd, R-Tech Ueno Ltd, Kaken Pharmaceutical Co., Ltd, Senju Pharmaceutical Co., Ltd, KOWA Pharmaceutical Co., Ltd, and MSD KK. Masayuki Tatemichi has received consultant fee from Topcon Corporation.

Compliance with Ethics Guidelines

This study was approved by the Review Board of Jikei University School of Medicine [No. 17–196 (4617)]. Only patients who signed informed consent forms through the process according to the principles of the Helsinki declaration were enrolled in the study.

Author information

Authors and Affiliations

  1. Department of Ophthalmology, The Jikei University, School of Medicine, Tokyo, Japan

    Tadashi Nakano

  2. Olympia Eye Hospital, Tokyo, Japan

    Rishu Inoue

  3. Ueno Ganka Clinic, Tokyo, Japan

    Tairo Kimura

  4. Suzumura Ganka Clinic, Tokyo, Japan

    Hirotaka Suzumura

  5. Nishikamakura Tanino Clinic, Kanagawa, Japan

    Tomihiko Tanino

  6. Department of Ophthalmology, Itabashi Hospital, Nihon University, Tokyo, Japan

    Yoshio Yamazaki

  7. Yoshikawa Eye Clinic, Tokyo, Japan

    Keiji Yoshikawa

  8. Department of Preventive Medicine, Tokai University, School of Medicine, Kanagawa, Japan

    Masayuki Tatemichi

Authors
  1. Tadashi Nakano
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rishu Inoue
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Tairo Kimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hirotaka Suzumura
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tomihiko Tanino
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yoshio Yamazaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Keiji Yoshikawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Masayuki Tatemichi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Masayuki Tatemichi.

Additional information

Enhanced content

To view enhanced content for this article go to http://www.medengine.com/Redeem/BFD4F0602867D3FE.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Nakano, T., Inoue, R., Kimura, T. et al. Effects of Brinzolamide, a Topical Carbonic Anhydrase Inhibitor, on Corneal Endothelial Cells. Adv Ther 33, 1452–1459 (2016). https://doi.org/10.1007/s12325-016-0373-y

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12325-016-0373-y

Keywords

Search

Navigation